137.7K XNAS Volume
XNAS 14 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Lawrence M. Blatt | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 140,103 | 140,103 | - | - | Stock Option (Right to Buy) | |
| Lesley Ann Calhoun | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 47,271 | 47,271 | - | - | Stock Option (Right to Buy) | |
| Julian A. Symons | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 21,693 | 21,693 | - | - | Stock Option (Right to Buy) | |
| Hardean E. Achneck | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2024 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Blatt | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Sep 2024 | 33,920 | 33,920 | - | - | Stock Option (Right to Buy) | |
| Lesley Ann Calhoun | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Sep 2024 | 10,880 | 10,880 | - | - | Stock Option (Right to Buy) | |
| Julian A. Symons | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Sep 2024 | 10,880 | 10,880 | - | - | Stock Option (Right to Buy) | |
| Heather Elizabeth Preston | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2024 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Margarita Chavez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2024 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| James Scopa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Bridget A. Martell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Carole L. Nuechterlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Blatt | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 965,435 | 965,435 | - | - | Stock Option (Right to Buy) | |
| Lesley Ann Calhoun | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 308,940 | 308,940 | - | - | Stock Option (Right to Buy) | |
| Julian A. Symons | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 72,000 | 72,000 | - | - | Stock Option (Right to Buy) | |
| Matthew W. McClure | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 72,000 | 72,000 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Blatt | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 80,850 | 0 | - | - | Stock Option (Right to Buy) | |
| Bridget Martell A. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Matthew McClure W. | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 23,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Symons A. Julian | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 18,750 | 18,750 | - | - | Stock Option (Right to Buy) | |
| Bech Nielsen Jack | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Lesley Calhoun Ann | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 51,833 | 51,833 | - | - | Stock Option (Right to Buy) | |
| Ann Lesley Calhoun | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 74,998 | 74,998 | - | - | Stock Option (Right to Buy) | |
| Blatt Lawrence M. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 57,749 | 57,749 | - | - | Stock Option (Right to Buy) | |
| Calhoun Ann Lesley | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 18,750 | 18,750 | - | - | Stock Option (Right to Buy) | |
| Symons Julian A. | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 200,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Blatt | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 230,999 | 230,999 | - | - | Stock Option (Right to Buy) | |
| Blatt Lawrence M. | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 450,000 | 0 | - | - | Stock Option (Right to Buy) | |
| McClure Matthew W. | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 16,428 | 16,428 | - | - | Stock Option (Right to Buy) | |
| M. Blatt Lawrence | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 132,352 | 132,352 | - | - | Stock Option (Right to Buy) | |
| Bridget A. Martell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 8,823 | 8,823 | - | - | Stock Option (Right to Buy) | |
| Julian Symons A. | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 26,250 | 0 | - | - | Stock Option (Right to Buy) | |
| Ann Calhoun Lesley | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 26,250 | 0 | - | - | Stock Option (Right to Buy) | |
| Scopa James | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 8,823 | 8,823 | - | - | Stock Option (Right to Buy) | |
| Lesley Calhoun Ann | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 105,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Nuechterlein L. Carole | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 4,411 | 4,411 | - | - | Stock Option (Right to Buy) | |
| McClure Matthew W. | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 75,183 | 75,183 | - | - | Stock Option (Right to Buy) | |
| Blatt Lawrence M. | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 323,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Nielsen Bech Jack | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 4,411 | 4,411 | - | - | Stock Option (Right to Buy) | |
| Scopa James | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Matthew McClure W. | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 255,626 | 0 | - | - | Stock Option (Right to Buy) | |
| A. Julian Symons | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 105,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Symons Julian A. | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 58,822 | 58,822 | - | - | Stock Option (Right to Buy) | |
| Lesley Ann Calhoun | See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 176,237 | 0 | - | - | Stock Option (Right to Buy) | |
| Matthew W. McClure | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 65,713 | 65,713 | - | - | Stock Option (Right to Buy) | |
| Nuechterlein Carole L. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Symons Julian A. | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 74,998 | 74,998 | - | - | Stock Option (Right to Buy) | |
| Matthew W. McClure | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 92,000 | 0 | - | - | Stock Option (Right to Buy) | |
| James Scopa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Carole L. Nuechterlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Blatt | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 242,500 | 242,500 | - | - | Stock Option (Right to Buy) | |
| Lesley Ann Calhoun | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 78,750 | 78,750 | - | - | Stock Option (Right to Buy) | |
| Leonid Beigelman | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 169,500 | 169,500 | - | - | Stock Option (Right to Buy) | |
| Lucinda Y. Quan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 78,750 | 78,750 | - | - | Stock Option (Right to Buy) | |
| Julian A. Symons | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 78,750 | 78,750 | - | - | Stock Option (Right to Buy) | |
| Matthew W. McClure | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Blatt | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 161,700 | 161,700 | - | - | Stock Option (Right to Buy) | |
| Lesley Ann Calhoun | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 52,500 | 52,500 | - | - | Stock Option (Right to Buy) | |
| Leonid Beigelman | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 113,000 | 113,000 | - | - | Stock Option (Right to Buy) | |
| Lucinda Y. Quan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 52,500 | 52,500 | - | - | Stock Option (Right to Buy) | |
| Julian A. Symons | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Matthew W. McClure | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 46,000 | 46,000 | - | - | Stock Option (Right to Buy) | |
| Jack Bech Nielsen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Bridget A. Martell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Carole L. Nuechterlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Thomas Woiwode | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Julian A. Symons | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2022 | 105,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| Julian A. Symons | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2022 | 26,250 | 26,250 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Blatt | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 80,850 | 80,850 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Blatt | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 323,400 | 323,400 | - | - | Stock Option (Right to Buy) | |
| Lesley Ann Calhoun | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 105,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| Lesley Ann Calhoun | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 26,250 | 26,250 | - | - | Stock Option (Right to Buy) | |
| Leonid Beigelman | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 56,700 | 56,700 | - | - | Stock Option (Right to Buy) | |
| Leonid Beigelman | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 226,800 | 226,800 | - | - | Stock Option (Right to Buy) | |
| Lucinda Y. Quan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 26,250 | 26,250 | - | - | Stock Option (Right to Buy) | |
| Lucinda Y. Quan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 105,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| Jack B. Nielsen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Carole L. Nuechterlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Thomas Woiwode | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 26 Apr 2021 | 8,385 | 8,385 | - | 0 | Common Stock | |
| Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 26 Apr 2021 | 8,385 | 0 | - | 0 | Common Stock | |
| Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 26 Apr 2021 | 485,979 | 1,943,916 | - | 0 | Common Stock | |
| Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 26 Apr 2021 | 2,226 | 2,226 | - | 0 | Common Stock | |
| Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 26 Apr 2021 | 9,720 | 9,720 | - | 0 | Common Stock | |
| Thomas Woiwode | Director | Other type of transaction at price $ 0.00 per share. | 26 Apr 2021 | 9,720 | 0 | - | 0 | Common Stock | |
| Lawrence M. Blatt | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2020 | 450,000 | 450,000 | - | - | Stock Option (Right to Buy) | |
| Lesley Ann Calhoun | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2020 | 176,237 | 176,237 | - | - | Stock Option (Right to Buy) | |
| Leonid Beigelman | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2020 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Lucinda Y. Quan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2020 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Julian A. Symons | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2020 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 3,394 | 0 | - | - | Series B-1 Preferred Stock | ||
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 3,394 | 0 | - | - | Series B-1 Preferred Stock | ||
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 50,712 | 0 | - | - | Series B-1 Preferred Stock | ||
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 13,671 | 0 | - | - | Series A Preferred Stock | ||
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 13,671 | 0 | - | - | Series A Preferred Stock | ||
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 122,601 | 0 | - | - | Series A Preferred Stock | ||
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 41,016 | 0 | - | - | Series A Preferred Stock | ||
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 1,452 | 18,517 | - | - | Common Stock | ||
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 1,452 | 18,517 | - | - | Common Stock | ||
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 21,695 | 113,423 | - | - | Common Stock | ||
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 3,394 | 17,065 | - | - | Common Stock | ||
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 3,394 | 17,065 | - | - | Common Stock | ||
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 50,712 | 91,728 | - | - | Common Stock | ||
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 13,671 | 13,671 | - | - | Common Stock | ||
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 13,671 | 13,671 | - | - | Common Stock | ||
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 122,601 | 122,601 | - | - | Common Stock | ||
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 41,016 | 41,016 | - | - | Common Stock | ||
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 1,452 | 0 | - | - | Series B-2 Preferred Stock | ||
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 1,452 | 0 | - | - | Series B-2 Preferred Stock | ||
| Lawrence M. Blatt | Chief Executive Officer | 20 Oct 2020 | 21,695 | 0 | - | - | Series B-2 Preferred Stock | ||
| Carole L. Nuechterlein | Director | 20 Oct 2020 | 283,550 | 0 | - | - | Series B-2 Preferred Stock | ||
| Carole L. Nuechterlein | Director | 20 Oct 2020 | 662,799 | 0 | - | - | Series B-1 Preferred Stock | ||
| Carole L. Nuechterlein | Director | 20 Oct 2020 | 2,145,991 | 0 | - | - | Series A Preferred Stock | ||
| Carole L. Nuechterlein | Director | 20 Oct 2020 | 283,550 | 3,092,340 | - | - | Common Stock | ||
| Carole L. Nuechterlein | Director | 20 Oct 2020 | 662,799 | 2,808,790 | - | - | Common Stock | ||
| Carole L. Nuechterlein | Director | 20 Oct 2020 | 2,145,991 | 2,145,991 | - | - | Common Stock | ||
| Thomas Woiwode | Director | 20 Oct 2020 | 198,485 | 662,444 | - | - | Common Stock | ||
| Thomas Woiwode | Director | 20 Oct 2020 | 463,959 | 463,959 | - | - | Common Stock | ||
| Thomas Woiwode | Director | 20 Oct 2020 | 198,485 | 0 | - | - | Series B-2 Preferred Stock | ||
| Thomas Woiwode | Director | 20 Oct 2020 | 198,839 | 2,344,830 | - | - | Common Stock | ||
| Thomas Woiwode | Director | 20 Oct 2020 | 2,145,991 | 2,145,991 | - | - | Common Stock | ||
| Thomas Woiwode | Director | 20 Oct 2020 | 85,065 | 2,429,895 | - | - | Common Stock | ||
| Thomas Woiwode | Director | 20 Oct 2020 | 85,065 | 0 | - | - | Series B-2 Preferred Stock | ||
| Thomas Woiwode | Director | 20 Oct 2020 | 463,959 | 0 | - | - | Series B-1 Preferred Stock | ||
| Thomas Woiwode | Director | 20 Oct 2020 | 198,839 | 0 | - | - | Series B-1 Preferred Stock | ||
| Thomas Woiwode | Director | 20 Oct 2020 | 2,145,991 | 0 | - | - | Series A Preferred Stock | ||
| Thomas Woiwode | Director | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 20 Oct 2020 | 200,000 | 862,444 | - | 15 | 3,000,000 | Common Stock |
| Leonid Beigelman | Director, President | 20 Oct 2020 | 50,781 | 214,623 | - | - | Common Stock | ||
| Leonid Beigelman | Director, President | 20 Oct 2020 | 163,842 | 163,842 | - | - | Common Stock | ||
| Leonid Beigelman | Director, President | 20 Oct 2020 | 13,559 | 13,559 | - | - | Common Stock | ||
| Leonid Beigelman | Director, President | 20 Oct 2020 | 13,559 | 13,559 | - | - | Common Stock | ||
| Leonid Beigelman | Director, President | 20 Oct 2020 | 3,359 | 16,918 | - | - | Common Stock | ||
| Leonid Beigelman | Director, President | 20 Oct 2020 | 3,359 | 16,918 | - | - | Common Stock | ||
| Leonid Beigelman | Director, President | 20 Oct 2020 | 21,724 | 236,347 | - | - | Common Stock | ||
| Leonid Beigelman | Director, President | 20 Oct 2020 | 1,437 | 18,355 | - | - | Common Stock | ||
| Leonid Beigelman | Director, President | 20 Oct 2020 | 1,437 | 18,355 | - | - | Common Stock | ||
| Leonid Beigelman | Director, President | 20 Oct 2020 | 163,842 | 0 | - | - | Series A Preferred Stock | ||
| Leonid Beigelman | Director, President | 20 Oct 2020 | 13,559 | 0 | - | - | Series A Preferred Stock | ||
| Leonid Beigelman | Director, President | 20 Oct 2020 | 13,559 | 0 | - | - | Series A Preferred Stock | ||
| Leonid Beigelman | Director, President | 20 Oct 2020 | 50,781 | 0 | - | - | Series B-1 Preferred Stock | ||
| Leonid Beigelman | Director, President | 20 Oct 2020 | 3,359 | 0 | - | - | Series B-1 Preferred Stock | ||
| Leonid Beigelman | Director, President | 20 Oct 2020 | 3,359 | 0 | - | - | Series B-1 Preferred Stock | ||
| Leonid Beigelman | Director, President | 20 Oct 2020 | 21,724 | 0 | - | - | Series B-2 Preferred Stock | ||
| Leonid Beigelman | Director, President | 20 Oct 2020 | 1,437 | 0 | - | - | Series B-2 Preferred Stock | ||
| Leonid Beigelman | Director, President | 20 Oct 2020 | 1,437 | 0 | - | - | Series B-2 Preferred Stock | ||
| Lucinda Y. Quan | See Remarks | 20 Oct 2020 | 726 | 0 | - | - | Series B-2 Preferred Stock | ||
| Lucinda Y. Quan | See Remarks | 20 Oct 2020 | 6,835 | 6,835 | - | - | Common Stock | ||
| Lucinda Y. Quan | See Remarks | 20 Oct 2020 | 1,697 | 8,532 | - | - | Common Stock | ||
| Lucinda Y. Quan | See Remarks | 20 Oct 2020 | 726 | 9,258 | - | - | Common Stock | ||
| Lucinda Y. Quan | See Remarks | 20 Oct 2020 | 6,835 | 0 | - | - | Series A Preferred Stock | ||
| Lucinda Y. Quan | See Remarks | 20 Oct 2020 | 1,697 | 0 | - | - | Series B-1 Preferred Stock | ||
| Julian A. Symons | See Remarks | 20 Oct 2020 | 1,452 | 0 | - | - | Series B-2 Preferred Stock | ||
| Julian A. Symons | See Remarks | 20 Oct 2020 | 13,671 | 389,218 | - | - | Common Stock | ||
| Julian A. Symons | See Remarks | 20 Oct 2020 | 3,394 | 392,612 | - | - | Common Stock | ||
| Julian A. Symons | See Remarks | 20 Oct 2020 | 1,452 | 394,064 | - | - | Common Stock | ||
| Julian A. Symons | See Remarks | 20 Oct 2020 | 13,671 | 0 | - | - | Series A Preferred Stock | ||
| Julian A. Symons | See Remarks | 20 Oct 2020 | 3,394 | 0 | - | - | Series B-1 Preferred Stock |